Citigroup
BLPH

Citigroup’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Citigroup’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-86
Closed – – 6940
2022
Q1 		$0 Buy
+86
New +$205 ﹤0.01% 6881
2021
Q3 		– Sell
-50
Closed – – 6574
2021
Q2 		$0 Sell
50
-249
-83% -$1.12K ﹤0.01% 6626
2021
Q1 		$2K Sell
299
-487
-62% -$3.39K ﹤0.01% 6076
2020
Q4 		$5K Buy
786
+571
+266% +$4.67K ﹤0.01% 7130
2020
Q3 		$2K Sell
215
-254
-54% -$2.99K ﹤0.01% 7344
2020
Q2 		$6K Buy
+469
New +$6.56K ﹤0.01% 7243
2016
Q1 		– Sell
-2
Closed – – 7939
2015
Q4 		$0 Sell
2
-90
-98% -$4.36K ﹤0.01% 8026
2015
Q3 		$7K Buy
+92
New +$7.09K ﹤0.01% 6614

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Citigroup's BLPH Position: Q2 2022 in Review

Citigroup sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2022, closing a stake of 86 shares.

Citigroup first reported a position in BLPH in Q3 2015 and held it in 8 quarters. The position peaked at $7K in Q3 2015. 19 funds tracked by Wall St. Rank hold BLPH as of Q2 2022.

  • Citigroup reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Citigroup sold 86 Bellerophon Therapeutics, Inc. shares in Q2 2022.
  • Citigroup first reported a position in Bellerophon Therapeutics, Inc. in Q3 2015 and held it in 8 quarters.
  • Citigroup's Bellerophon Therapeutics, Inc. position peaked at $7K in Q3 2015.
  • 19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.